Therefore, a new drug that inhibits the NF-κB expression and activation may induce apoptosis of cancel cells and reduce the angiogenesis of pancreatic cancer, thus enhancing the anti-tumor activity of gemcitabine and potentially benefiting patients with pancreatic cancer. This evidence concerns the gene NFKB1 and pancreatic neoplasm.